Source: Eur Respir J 2013; 42: 272-279
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Nicolas Amabile, Christophe Guignabert, David Montani, Yerem Yeghiazarians, Chantal M. Boulanger, Marc Humbert. Cellular microparticles in the pathogenesis of pulmonary hypertension. Eur Respir J 2013; 42: 272-279

Member's Comments

No comment yet.

Related content which might interest you: Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2015; 46: 431-443 Year: 2015 Endothelial cells in the pathogenesis of pulmonary arterial hypertension Source: Eur Respir J, 58 (3) 2003957; 10.1183/13993003.03957-2020 Year: 2021 Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension Source: Eur Respir J, 58 (5) 2000653; 10.1183/13993003.00653-2020 Year: 2021 Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with BMPR2 mutation Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 The Role of Inflammation in promoting pulmonary hypertension in idiopatchi and connective tissue disease-associated PAH Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Endothelial NO and its pathophysiologic regulation Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease Year: 2007 Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Crucial role of thrombin-activated fibrinolysis inhibitor in the pathogenesis of chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Novel insights into the pathogenesis of pulmonary arterial hypertension Source: Virtual Congress 2020 – Pulmonary vascular diseases Year: 2020 MIF/CD74 contributes to the endothelial pro-inflammatory phenotype in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension Source: Eur Respir J, 58 (2) 2101645; 10.1183/13993003.01645-2021 Year: 2021 CFTR involvement in the pathogenesis of pulmonary arterial hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Analysis of pulmonary endothelial microparticles, haemodynamics and functional class in pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature Source: Eur Respir J 2014; 44: 1275-1288 Year: 2014 Updates in pulmonary hypertension and other pulmonary vascular diseases Source: Breathe, 15 (3) 241; 10.1183/20734735.0187-2019 Year: 2019 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Inflammatory cell accumulation in pulmonary arteries is associated with systemic inflammation in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 Novel biomarkers in idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010 Pulmonary hypertension: pathophysiology and diagnosis Source: Annual Congress 2007 - PG19 - Pulmonary vascular disorders: diagnosis and treatment Year: 2007 Pulmonary hypertension in sickle cell disease Source: Annual Congress 2007 - ACCP1 - Pulmonary hypertension in sickle cell disease Year: 2007